Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C

Digestive Diseases

Volumn 18, Issue 3, 2000, Pages 107-116

  Fontana, Robert J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b 3912 Taubman Center ^*  (United States)

Author keywords

Adverse events; Hepatitis C; Interferon; Neuropsychiatric toxicity; Ribavirin

Indexed keywords

ADRENALIN; ALPHA INTERFERON; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIPYRETIC ANALGESIC AGENT; ANTIVIRUS AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; NEFAZODONE; OPIATE RECEPTOR; PAROXETINE; REBETRON; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT;

ADRENERGIC SYSTEM; ALGORITHM; BLOOD TOXICITY; CHRONIC HEPATITIS; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG CONTRAINDICATION; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEPATITIS C; HUMAN; MENTAL DISEASE; NEUROENDOCRINE SYSTEM; NEUROTOXICITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIVIRAL AGENTS; ANXIETY; CHRONIC DISEASE; COGNITION; DEPRESSION; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERON-ALPHA; RIBAVIRIN; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 0034463917     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051384     Document Type: Review

References (78)

1. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
2. Management of hepatitis C
3. Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials
4. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
5. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
6. Combination therapy with Peg interferon-alfa 2a (ZPEG-IFN) and ribavirin in the treatment of patients with chronic hepatitis C: A phase II open-label study
7. A controlled, randomized multicenter descending dose phase II trial of pegylated interferon alfa-2A vs. standard interferon alfa-2A for treatment of chronic hepatitis C
8. Modeling the impact of alpha interferon treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view
9. A randomized controlled trial of maintenance interferon therapy for patients with chronic hepatitis C and persistent viremia
10. Side effects of high-dose interferon therapy for chronic hepatitis C
11. Clinical toxicity of the interferons
12. Side effects of alpha interferon in chronic hepatitis C
13. Suicide associated with alfa-interferon therapy for chronic viral hepatitis
14. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multi-center trial
15. Central nervous system toxicity of interferons and other cytokines
16. Retinal complications during interferon therapy for chronic hepatitis C
17. Sudden hearing loss associated with interferon
18. Neurotoxicity of interferon-alpha
19. Central nervous system toxicity of interferon
20. Interferon-induced organic mental disorders with unsuspected preexisiting neurologic abnormalities
21. Seizures during alpha interferon therapy
22. Seizures associated with low-dose α-interferon
23. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon
24. Peripheral polyneuropathy during treatment with alpha-2 interferon
25. Severe neuropathy associated with low dose recombinant interferon-alpha
26. Peripheral neuropathy associated with essential mixed cryoglobulinemia: A role for hepatitis C virus infection
27. High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryogobulinemia
28. Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection
29. Hepatitis C infection, cryoglobulinemia, and vasculitic neuropathy
30. Interferon alfa-associated retinopathy
31. Neurovisual impairment: A frequent complication of alpha-interferon treatment in chronic viral hepatitis
32. Mapped auditory evoked potentials before and after IFN treatment
33. Psychiatric complications of long-term interferon alfa therapy
34. Interferons as mediators of psychiatric morbidity
35. Effect of interferon-α treatment of chronic hepatitis C on health-related quality of life
36. Hepatitis C virus infection: Quality of life and side effects of treatment
37. Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha
38. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha
39. One month prevalence of mental disorders in the United States
40. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer
41. Pattern of neurobehavioral deficits associated with IFNa therapy for leukemia
42. Cognitive impairment and major depression: Beyond the psuedodementia syndrome
43. High prevalence of sleep disturbance in cirrhosis
44. Subclinical encephalopathy
45. Musculoskeletal pain and fatigue are associated with chronic hepatitis C
46. Morbidity of chronic hepatitis C as seen in a tertiary care medical center
47. The impact of diagnosis of hepatitis C on quality of life
48. Hepatitis C virus and depression in drug users
49. Psychopathology in male and female intravenous drug users with and without HIV infection
50. Psychiatric symptoms in polysubstance abusers: Relationship to race, sex, and age
51. Potential mechanisms of interferon neurotoxicity
52. Cytokine therapeutics: Lessons from interferon alpha
53. Mechanisms of fever induced by recombinant human interferon
54. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration
55. Neurotoxicity of IFN
56. Effects of interferon alpha 2a on catecholamines and lymphocyte beta2 adrenoreceptors in healthy humans
57. Resting plasma catecholamine concentrations in patients with depression and anxiety
58. High plasma norepinephrine levels in patients with major affective disorders
59. Assessing depression in primary care practice with the BDI and the Hamilton Rating Scale for depression
60. Effects of IFN-alpha and IFN-gamma and cAMP on the transcriptional regulation of the serotonin transporter
61. Cortisol stimulation by recombinant IFNa
62. Subacute effects of interferon-alpha2 on adrenocorticotrophic hormone, cortisol, growth hormone, and prolactin in humans
63. Differences in plasma ACTH and cortisol between depressed patients and normal control
64. Biological 'markers' of endogenous depression. Effect of age, severity of illness, weight loss, and polarity
65. Plasma levels of cyclic GMP, immune parameters , and depressive status during IFN therapy
66. Treatment of neurotoxic side effects of interferon-a with naltrexone
67. Incidence of high depressive symptoms in patients with chronic hepatitis C using the Center for Epidemiologic Studies Depression Scale (CES-D)
68. Validation of the Center for Epidemiologic Studies Depression Scale (CES-D) in hepatitis C patients
69. Emotional distress during IFN and ribavirin combination therapy of hepatitis C: A prospective study
70. The brief symptom inventory: An introductory report
71. Interferon-alpha can be used successfully in patients with hepatitis C virus positive chronic hepatitis who have a psychiatric illness
72. Interferon alpha-induced depression in chronic hepatitis C patients: Comparison between different types of interferon alpha
73. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state
74. Sucessful treatment of IFN-α-induced mood disorder with nortriptyline
75. Fluoxetine treatment of depression caused by IFN-α
76. Five cases of interferon-alpha-induced depression treated with anti-depressant therapy
77. Pretreatment with the antidepressant paroxetine prevents cytokine induced depression during interferon-alpha therapy for malignant melanoma